Cantor Fitzgerald Has Negative View of CLDX FY2025 Earnings
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Celldex Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($3.67) per share for the year, down from their previous estimate […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Celldex Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn ($3.67) per share for the year, down from their previous estimate […]
